Latest News


Filter by tags: Clinical trial Clear all tag filters

3 news articles found

Rusatom Healthcare, part of state nuclear corporation Rosatom, will build Russia’s first radiopharmaceutical plant to meet global GMP good manufacturing practice standards. The new production facility will be in Obninsk at the site of LYa Karpov Scientific Research Institute of Physics & Chemistry (NIFKhl) and will produce drugs for targeted cancer therapy. The design of pharmaceutical production will be carried out by the Central Design and Technological Institute. Pre-design work is planned to be completed this year, for commissioning in 2024  production in early 2025.

Date: Friday, 07 August 2020
Original article:

The Australian Nuclear Science and Technology Organisation (Ansto) said  a new radioactive variation of the element scandium, scandium-47, had been produced in the OPAL reactor.

Date: Tuesday, 24 March 2020
Original article:

A new radioactive version of the element scandium has been produced in Australia's OPAL reactor for the first time. Scandium-47 has the potential for theranostic use, that is, both as a therapeutic drug and a diagnostic agent, and has similar properties to lutetium-177, which is already being used in clinical trials.

Date: Friday, 20 March 2020
Original article:




No Tags found.